spatial transcriptomics geomx dsp Search Results


90
Spatial Transcriptomics Inc geomx dsp set
<t>GeoMx</t> spatial profiling reveals pro-inflammatory conversion of TAMs in DC patients (A) Schematic for GeoMx spatial transcriptomics profiling of pre- and post-treatment biopsies from non-DC (n = 3 patients, 30 ROIs) and DC (n = 3 patients, 33 ROIs) patients. Representative images of morphology marker staining and corresponding segmentation are displayed for a single ROI. (B) Volcano plot showing differentially expressed genes in DC patient CD68 + areas after bexmarilimab therapy. (C) Bubble plots of top up- and downregulated pathways in CD68 + tumor areas of DC patients after bexmarilimab therapy (gene set enrichment analysis). (D) Volcano plot showing differentially expressed genes in non-DC patient CD68 + areas after bexmarilimab therapy. (E) Bubble plots of top up- and downregulated pathways in CD68 + tumor areas of non-DC patients after bexmarilimab therapy (gene set enrichment analysis). (F) Heatmap of M1 and M2 macrophage gene scores on CD68 + area. Red color indicates higher M1 or M2 gene expression than overall gene expression, blue color lower. Each tile represents median of patient’s ROIs. (G) Bar graph of M2/M1 score ratios corresponding to scores shown in (F). Each point represents patient median across ROIs and each bar patient group median. (H) Volcano plot showing differentially activated pathways between CD68 + areas of non-DC and DC patients’ pre-treatment biopsies (gene set enrichment analysis, n = 16 ROIs [non-DC], n = 10 ROIs [DC]). Pre, pre-treatment biopsy; Post, post-treatment biopsy; ROI, region of interest; P adj , Benjamini-Hochberg-adjusted p value; ∗∗ P adj < 0.01; ∗ P adj < 0.05; ns, not significant. In (C) and (E), red color denotes pathway activation and blue downregulation. See also <xref ref-type=Figures S7 – , and Supplementary and . " width="250" height="auto" />
Geomx Dsp Set, supplied by Spatial Transcriptomics Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/spatial+transcriptomics+geomx+dsp/geomx+dsp+set/pmc10772343-433-0-10
Average 90 stars, based on 1 article reviews
geomx dsp set - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Spatial Transcriptomics Inc geomx dsp
<t>GeoMx</t> spatial profiling reveals pro-inflammatory conversion of TAMs in DC patients (A) Schematic for GeoMx spatial transcriptomics profiling of pre- and post-treatment biopsies from non-DC (n = 3 patients, 30 ROIs) and DC (n = 3 patients, 33 ROIs) patients. Representative images of morphology marker staining and corresponding segmentation are displayed for a single ROI. (B) Volcano plot showing differentially expressed genes in DC patient CD68 + areas after bexmarilimab therapy. (C) Bubble plots of top up- and downregulated pathways in CD68 + tumor areas of DC patients after bexmarilimab therapy (gene set enrichment analysis). (D) Volcano plot showing differentially expressed genes in non-DC patient CD68 + areas after bexmarilimab therapy. (E) Bubble plots of top up- and downregulated pathways in CD68 + tumor areas of non-DC patients after bexmarilimab therapy (gene set enrichment analysis). (F) Heatmap of M1 and M2 macrophage gene scores on CD68 + area. Red color indicates higher M1 or M2 gene expression than overall gene expression, blue color lower. Each tile represents median of patient’s ROIs. (G) Bar graph of M2/M1 score ratios corresponding to scores shown in (F). Each point represents patient median across ROIs and each bar patient group median. (H) Volcano plot showing differentially activated pathways between CD68 + areas of non-DC and DC patients’ pre-treatment biopsies (gene set enrichment analysis, n = 16 ROIs [non-DC], n = 10 ROIs [DC]). Pre, pre-treatment biopsy; Post, post-treatment biopsy; ROI, region of interest; P adj , Benjamini-Hochberg-adjusted p value; ∗∗ P adj < 0.01; ∗ P adj < 0.05; ns, not significant. In (C) and (E), red color denotes pathway activation and blue downregulation. See also <xref ref-type=Figures S7 – , and Supplementary and . " width="250" height="auto" />
Geomx Dsp, supplied by Spatial Transcriptomics Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/spatial+transcriptomics+geomx+dsp/geomx+dsp/pmc11867587-14-28-7
Average 90 stars, based on 1 article reviews
geomx dsp - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Spatial Transcriptomics Inc geomx-dsp data
<t>GeoMx</t> spatial profiling reveals pro-inflammatory conversion of TAMs in DC patients (A) Schematic for GeoMx spatial transcriptomics profiling of pre- and post-treatment biopsies from non-DC (n = 3 patients, 30 ROIs) and DC (n = 3 patients, 33 ROIs) patients. Representative images of morphology marker staining and corresponding segmentation are displayed for a single ROI. (B) Volcano plot showing differentially expressed genes in DC patient CD68 + areas after bexmarilimab therapy. (C) Bubble plots of top up- and downregulated pathways in CD68 + tumor areas of DC patients after bexmarilimab therapy (gene set enrichment analysis). (D) Volcano plot showing differentially expressed genes in non-DC patient CD68 + areas after bexmarilimab therapy. (E) Bubble plots of top up- and downregulated pathways in CD68 + tumor areas of non-DC patients after bexmarilimab therapy (gene set enrichment analysis). (F) Heatmap of M1 and M2 macrophage gene scores on CD68 + area. Red color indicates higher M1 or M2 gene expression than overall gene expression, blue color lower. Each tile represents median of patient’s ROIs. (G) Bar graph of M2/M1 score ratios corresponding to scores shown in (F). Each point represents patient median across ROIs and each bar patient group median. (H) Volcano plot showing differentially activated pathways between CD68 + areas of non-DC and DC patients’ pre-treatment biopsies (gene set enrichment analysis, n = 16 ROIs [non-DC], n = 10 ROIs [DC]). Pre, pre-treatment biopsy; Post, post-treatment biopsy; ROI, region of interest; P adj , Benjamini-Hochberg-adjusted p value; ∗∗ P adj < 0.01; ∗ P adj < 0.05; ns, not significant. In (C) and (E), red color denotes pathway activation and blue downregulation. See also <xref ref-type=Figures S7 – , and Supplementary and . " width="250" height="auto" />
Geomx Dsp Data, supplied by Spatial Transcriptomics Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/spatial+transcriptomics+geomx+dsp/geomx+dsp+data/pmc11785740__41467_2025_56237_MOESM3_ESM-94-7-9
Average 90 stars, based on 1 article reviews
geomx-dsp data - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Spatial Transcriptomics Inc geomx dsp barcode
<t>GeoMx</t> spatial profiling reveals pro-inflammatory conversion of TAMs in DC patients (A) Schematic for GeoMx spatial transcriptomics profiling of pre- and post-treatment biopsies from non-DC (n = 3 patients, 30 ROIs) and DC (n = 3 patients, 33 ROIs) patients. Representative images of morphology marker staining and corresponding segmentation are displayed for a single ROI. (B) Volcano plot showing differentially expressed genes in DC patient CD68 + areas after bexmarilimab therapy. (C) Bubble plots of top up- and downregulated pathways in CD68 + tumor areas of DC patients after bexmarilimab therapy (gene set enrichment analysis). (D) Volcano plot showing differentially expressed genes in non-DC patient CD68 + areas after bexmarilimab therapy. (E) Bubble plots of top up- and downregulated pathways in CD68 + tumor areas of non-DC patients after bexmarilimab therapy (gene set enrichment analysis). (F) Heatmap of M1 and M2 macrophage gene scores on CD68 + area. Red color indicates higher M1 or M2 gene expression than overall gene expression, blue color lower. Each tile represents median of patient’s ROIs. (G) Bar graph of M2/M1 score ratios corresponding to scores shown in (F). Each point represents patient median across ROIs and each bar patient group median. (H) Volcano plot showing differentially activated pathways between CD68 + areas of non-DC and DC patients’ pre-treatment biopsies (gene set enrichment analysis, n = 16 ROIs [non-DC], n = 10 ROIs [DC]). Pre, pre-treatment biopsy; Post, post-treatment biopsy; ROI, region of interest; P adj , Benjamini-Hochberg-adjusted p value; ∗∗ P adj < 0.01; ∗ P adj < 0.05; ns, not significant. In (C) and (E), red color denotes pathway activation and blue downregulation. See also <xref ref-type=Figures S7 – , and Supplementary and . " width="250" height="auto" />
Geomx Dsp Barcode, supplied by Spatial Transcriptomics Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/spatial+transcriptomics+geomx+dsp/geomx+dsp+barcode/10__1097_slash_hep__0000000000000866-250-16-26
Average 90 stars, based on 1 article reviews
geomx dsp barcode - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


GeoMx spatial profiling reveals pro-inflammatory conversion of TAMs in DC patients (A) Schematic for GeoMx spatial transcriptomics profiling of pre- and post-treatment biopsies from non-DC (n = 3 patients, 30 ROIs) and DC (n = 3 patients, 33 ROIs) patients. Representative images of morphology marker staining and corresponding segmentation are displayed for a single ROI. (B) Volcano plot showing differentially expressed genes in DC patient CD68 + areas after bexmarilimab therapy. (C) Bubble plots of top up- and downregulated pathways in CD68 + tumor areas of DC patients after bexmarilimab therapy (gene set enrichment analysis). (D) Volcano plot showing differentially expressed genes in non-DC patient CD68 + areas after bexmarilimab therapy. (E) Bubble plots of top up- and downregulated pathways in CD68 + tumor areas of non-DC patients after bexmarilimab therapy (gene set enrichment analysis). (F) Heatmap of M1 and M2 macrophage gene scores on CD68 + area. Red color indicates higher M1 or M2 gene expression than overall gene expression, blue color lower. Each tile represents median of patient’s ROIs. (G) Bar graph of M2/M1 score ratios corresponding to scores shown in (F). Each point represents patient median across ROIs and each bar patient group median. (H) Volcano plot showing differentially activated pathways between CD68 + areas of non-DC and DC patients’ pre-treatment biopsies (gene set enrichment analysis, n = 16 ROIs [non-DC], n = 10 ROIs [DC]). Pre, pre-treatment biopsy; Post, post-treatment biopsy; ROI, region of interest; P adj , Benjamini-Hochberg-adjusted p value; ∗∗ P adj < 0.01; ∗ P adj < 0.05; ns, not significant. In (C) and (E), red color denotes pathway activation and blue downregulation. See also <xref ref-type=Figures S7 – , and Supplementary and . " width="100%" height="100%">

Journal: Cell Reports Medicine

Article Title: Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trial

doi: 10.1016/j.xcrm.2023.101307

Figure Lengend Snippet: GeoMx spatial profiling reveals pro-inflammatory conversion of TAMs in DC patients (A) Schematic for GeoMx spatial transcriptomics profiling of pre- and post-treatment biopsies from non-DC (n = 3 patients, 30 ROIs) and DC (n = 3 patients, 33 ROIs) patients. Representative images of morphology marker staining and corresponding segmentation are displayed for a single ROI. (B) Volcano plot showing differentially expressed genes in DC patient CD68 + areas after bexmarilimab therapy. (C) Bubble plots of top up- and downregulated pathways in CD68 + tumor areas of DC patients after bexmarilimab therapy (gene set enrichment analysis). (D) Volcano plot showing differentially expressed genes in non-DC patient CD68 + areas after bexmarilimab therapy. (E) Bubble plots of top up- and downregulated pathways in CD68 + tumor areas of non-DC patients after bexmarilimab therapy (gene set enrichment analysis). (F) Heatmap of M1 and M2 macrophage gene scores on CD68 + area. Red color indicates higher M1 or M2 gene expression than overall gene expression, blue color lower. Each tile represents median of patient’s ROIs. (G) Bar graph of M2/M1 score ratios corresponding to scores shown in (F). Each point represents patient median across ROIs and each bar patient group median. (H) Volcano plot showing differentially activated pathways between CD68 + areas of non-DC and DC patients’ pre-treatment biopsies (gene set enrichment analysis, n = 16 ROIs [non-DC], n = 10 ROIs [DC]). Pre, pre-treatment biopsy; Post, post-treatment biopsy; ROI, region of interest; P adj , Benjamini-Hochberg-adjusted p value; ∗∗ P adj < 0.01; ∗ P adj < 0.05; ns, not significant. In (C) and (E), red color denotes pathway activation and blue downregulation. See also Figures S7 – , and Supplementary and .

Article Snippet: GeoMx DSP set (n = 6 patients; n = 180 spatial transcriptomics profiles) included all the patients who had paired pre- and post-treatment biopsies available, and had successful GeoMx DSP morphology staining and hybridization probe quantification.

Techniques: Marker, Staining, Gene Expression, Activation Assay